Platelet reactivity in patients and recurrent events post-stenting: results of the PREPARE POST-STENTING Study
about
Current status of high on-treatment platelet reactivity in patients with coronary or peripheral arterial disease: Mechanisms, evaluation and clinical implicationsType 2 Diabetes and ADP Receptor Blocker TherapyPersonalized antiplatelet therapy with P2Y12 receptor inhibitors: benefits and pitfallsClopidogrel and warfarin pharmacogenetic tests: what is the evidence for use in clinical practice?High residual platelet reactivity on clopidogrel: its significance and therapeutic challenges overcoming clopidogrel resistancePharmacogenomics of anti-platelet therapy: how much evidence is enough for clinical implementation?Thromboelastography: potential bedside tool to assess the effects of antiplatelet therapy?Aspirin and clopidogrel resistance: consideration and managementEvaluation of the TEG platelet mapping assay in blood donorsPlatelet function measured by VerifyNow identifies generalized high platelet reactivity in aspirin treated patientsEvaluation of the platelet response to clopidogrel with light transmittance aggregometry: peak aggregation or late aggregation?Pharmacokinetic drug evaluation of vorapaxar for secondary prevention after acute coronary syndrome.High platelet reactivity on clopidogrel therapy correlates with increased coronary atherosclerosis and calcification: a volumetric intravascular ultrasound study.Frequency of heparin/platelet factor 4-dependent platelet antibodies in patients undergoing angioplasty and stenting for cardiovascular disease and their role for on-clopidogrel platelet reactivity.Low platelet disaggregation predicts poor response to 150 mg clopidogrel in patients with elevated platelet reactivity.C-reactive protein and fibrin clot strength measured by thrombelastography after coronary stenting.Plasma and whole blood clot strength measured by thrombelastography in patients treated with clopidogrel during acute coronary syndromesInhibition of platelet aggregation by prostaglandin E1 (PGE1) in diabetic patients during therapy with clopidogrel and aspirin.Smoking Interaction with Clopidogrel; Another Smoker's Paradox?Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapyPlatelet function monitoring in patients on clopidogrel: What should we learn from GRAVITAS?Adenosine diphosphate-induced platelet-fibrin clot strength: a new thrombelastographic indicator of long-term poststenting ischemic eventsRacial differences in resistance to P2Y12 receptor antagonists in type 2 diabetic subjectsHostility and platelet reactivity in individuals without a history of cardiovascular disease events.Clopidogrel "resistance": where are we now?Clinical importance of aspirin and clopidogrel resistanceFactor XIII Val34Leu polymorphism and recurrent myocardial infarction in patients with coronary artery disease.Drug-drug interaction between clopidogrel and the proton pump inhibitors.Is platelet inhibition due to thienopyridines increased in elderly patients, in patients with previous stroke and patients with low body weight as a possible explanation of an increased bleeding risk?Influence of race and sex on thrombogenicity in a large cohort of coronary artery disease patientsEvaluation of clinical risk factors to predict high on-treatment platelet reactivity and outcome in patients with stable coronary artery disease (PREDICT-STABLE).Monitoring the effectiveness of antiplatelet therapy: opportunities and limitations.Effect of gender difference on platelet reactivity.Influence of paraoxonase-1 Q192R and cytochrome P450 2C19 polymorphisms on clopidogrel response.Association of PON1, P2Y12 and COX1 with Recurrent Ischemic Events in Patients with Extracranial or Intracranial Stenting.Platelet hyperreactivity in response to on- and off-pump coronary artery bypass grafting.Detailed analysis of periprocedural strokes in patients undergoing intracranial stenting in Stenting and Aggressive Medical Management for Preventing Recurrent Stroke in Intracranial Stenosis (SAMMPRIS).Platelet factor XIIIa release during platelet aggregation and plasma clot strength measured by thrombelastography in patients with coronary artery disease treated with clopidogrel.Thromboelastography for monitoring platelet function in unruptured intracranial aneurysm patients undergoing stent placement.Thrombelastography: current clinical applications and its potential role in interventional cardiology.
P2860
Q26771106-0CA00DE4-3BE9-4AFC-8B06-202D2EB0B19FQ26772996-C746AA92-47C0-4F30-9AF0-B1D17C5F0D54Q26775125-2CC52A4D-DFFB-4886-ACE8-E9377D1374B5Q26823542-8CCAD9D1-7208-4B5F-844C-18D9020239BFQ26824850-29937856-F0F4-41C9-A5C4-178D9AF7683AQ27022443-1B87C804-224F-40E1-AF6A-2A27D3376A1EQ28200486-FA228CA7-5322-41D5-88A1-015FE10CF82AQ28200610-662C24B1-F59C-47E9-948E-84EF16E6538CQ28219204-DE75DAE8-493A-48A9-9F8D-67AD79395533Q28220600-D6FDBF62-40D0-4ABE-9DCF-0EEF896850EDQ28221921-15B8D855-34FB-4857-80FD-730CA18F5185Q30238719-1FF03CD0-9FCC-47E4-BE22-BDCC0582E680Q30450312-9935ECFE-97AF-4D2E-B22F-5DA370580439Q33399119-2FACC15A-B43E-4B7E-9E3D-813B88418AD0Q33516375-8302235A-1984-4E23-A434-6477C5C87041Q33637814-4E6A9301-6BA9-496B-9620-89BCF15BE024Q33637824-387FDF23-6BEF-4A2F-9CCC-BC2E5B0B3639Q33637840-56BC443A-7D47-4BEC-93E6-56B70FCFE904Q33751272-0A2BC844-7ACE-44F9-93C0-1A28CC3866B9Q34019082-F7FA7BCD-E7C4-4AC6-9903-1B2FE9B0201DQ34035039-6A6A6144-3CFE-4143-9198-9FC3291B420DQ34111144-2A5A63D8-26BB-4B3D-883C-08DE2AA24EC5Q34186272-923B61B6-7B81-4667-BCD0-4F5ED6BFDD62Q34211191-42F90272-2F49-4E16-8582-F69D8EBDA26CQ34212563-E4715039-C50D-49E9-818C-8F9A5A8A3A70Q34390050-91373D4B-3D61-4EE4-8887-99ADE2FE8844Q34969512-32C54D3D-DAD7-4FCE-9CA6-CDE7E065E4B1Q34983154-8A75863D-123E-4767-9C94-B0AF9F10E12FQ35035904-08EEB3A1-0B48-4528-ABB3-904709700144Q35070799-0817D83D-458B-43C8-AE9F-AE30E97BAD40Q35208684-B92142D4-0F94-4B61-B406-7C65785F788DQ35373683-644DDF8B-A538-4474-9E79-058A84972D91Q35473568-D8D9EBC9-6993-4A0D-9BD0-46CB8FD256AAQ35832159-A415B055-8B34-4722-A8CD-1A6C1D1F1AE1Q35921906-E3B5A85A-FACC-4023-B15C-A390A5596945Q36374945-6F5A9CD2-3D34-44C2-926A-788C75DE9360Q36433515-754E8ECA-FAA9-4740-B140-A45F8C0CABF5Q36529548-7F86EA48-5E86-43F4-9706-B9F4B19FAFDBQ36589808-A51B878E-14CD-4AF1-832F-9ACBC378FE2CQ36664802-DC70AACC-6D64-41B5-9448-C6BBCAB2A650
P2860
Platelet reactivity in patients and recurrent events post-stenting: results of the PREPARE POST-STENTING Study
description
2005 nî lūn-bûn
@nan
2005 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2005 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
name
Platelet reactivity in patient ...... he PREPARE POST-STENTING Study
@ast
Platelet reactivity in patient ...... he PREPARE POST-STENTING Study
@en
Platelet reactivity in patient ...... he PREPARE POST-STENTING Study
@nl
type
label
Platelet reactivity in patient ...... he PREPARE POST-STENTING Study
@ast
Platelet reactivity in patient ...... he PREPARE POST-STENTING Study
@en
Platelet reactivity in patient ...... he PREPARE POST-STENTING Study
@nl
prefLabel
Platelet reactivity in patient ...... he PREPARE POST-STENTING Study
@ast
Platelet reactivity in patient ...... he PREPARE POST-STENTING Study
@en
Platelet reactivity in patient ...... he PREPARE POST-STENTING Study
@nl
P2093
P3181
P1476
Platelet reactivity in patient ...... he PREPARE POST-STENTING Study
@en
P2093
Ashwani K Bassi
Kazi A Zaman
Kevin P Bliden
Kirk Guyer
Paul A Gurbel
Peter W Cho
Rolf P Kreutz
Udaya S Tantry
P304
P3181
P356
10.1016/J.JACC.2005.07.041
P407
P577
2005-11-15T00:00:00Z